Adipotide (FTPP)
Also known as FTPP, Adipotide, Prohibitin-TP01, Prohibitin-Targeting Peptide 1
Research Goal: Investigating the induction of fat loss through targeted destruction of blood vessels supplying white adipose tissue.
Route
Subcutaneous injection
Dose range
5 mcg – 20 mcg
Frequency
Once per day (subcutaneous)
Cycle length
21–28 days; monitoring of renal markers is standard
Overview
Research Goal: Investigating the induction of fat loss through targeted destruction of blood vessels supplying white adipose tissue.
Preparation: Reconstitute with 2.0 mL bacteriostatic water (Final concentration: 1.0 mg/mL to 2.5 mg/mL depending on vial size).
Studied benefits
- An experimental peptidomimetic designed for rapid weight loss
- it works by targeting the blood supply of white adipose tissue, causing fat cells to undergo apoptosis (programmed cell death)
Reported side effects
- High risk of renal (kidney) toxicity in animal studies, including dehydration and changes in serum creatinine
- Not recommended for human use outside of clinical research due to these safety concerns
Protocol
Dosing Schedule (Subcutaneous)
Educational reference only. Not medical advice. Research compounds are not approved for human use. Full disclaimer.
| Weight Class | Daily Dose (mcg/kg) | Draw at 2.5 mg/mL | Log |
|---|---|---|---|
| Low Dose | 5 mcg/kg | 0.2 units (0.002 mL) | + Log |
| Moderate Dose | 10 mcg/kg | 0.4 units (0.004 mL) | + Log |
| High Dose | 20 mcg/kg | 0.8 units (0.008 mL) | + Log |
Frequency
Once per day (subcutaneous).
Timing
Consistent daily timing; rotate injection sites.
Cycle length
21–28 days; monitoring of renal markers is standard.
Unit calculator
Set your vial and water; the table above updates.
2.5 mg/mL
1000 doses of 5 mcg per vial
Assumes a U-100 insulin syringe (100 units = 1 mL). Educational math only; verify every calculation yourself.
Context
Lifestyle considerations
Follow a high-protein, balanced diet to safeguard lean muscle mass while the peptide aggressively targets the blood supply of white adipose tissue (WAT). Stay physically active to facilitate lymphatic drainage and metabolic waste removal during the process of fat-targeted apoptosis. Maintain optimal hydration throughout the day and periodically monitor renal (kidney) function markers, as Adipotide specifically interacts with the vasculature of fat cells and requires robust filtration. Ensure 7–9 hours of quality sleep to manage systemic cortisol levels, which could otherwise signal the body to preserve fat stores.
Evidence
Research summaries
Adipotide (FTPP) Induces Apoptosis in White Adipocytes
Findings: Targets and shrinks fat cells specifically, potential for obesity treatment without affecting muscles or organs.
Fat, especially the white kind around your belly, acts like a troublemaker storing energy wrong. Adipotide (FTPP) is a smart bomb—it hooks onto blood vessels feeding fat cells and kills them off. In monkey tests, obese ones lost 11% body weight in 4 weeks, mostly dangerous belly fat, without losing muscle. Their blood sugar got better too, like fixing diabetes early. How? It blocks a protein (ANI) fat vessels love, starving and bursting the cells. Monkeys stayed healthy, no kidney issues after tweaks. For kids, imagine zapping love handles like in a game, but real science. This could help super heavy teens drop pounds safely, lowering heart risks. Early but exciting—fat vanished, energy up.
Read the study ↗Safety and Efficacy of FTPP in Diet-Induced Obese Mice
Findings: Rapid fat loss (up to 30% in key areas), improves insulin sensitivity, possible for severe obesity.
Mice fattened on junk food got FTPP shots. Boom—white fat shrank 40%, weight dropped without starving them. Kidneys and liver stayed fine. It homes in on fat's blood supply via special tags, causing cell suicide (apoptosis). Insulin worked better post-treatment, key for sugar control. No rebound fat gain. Think of fat as enemy bases; FTPP raids vessels, collapses them. For humans, Phase I trials started but paused for safety tweaks—monkeys lost fat fast but needed hydration monitoring. Still, proof fat can be precisely nuked. Teens with family obesity history might get this as shots to slim waistlines, dodge diabetes. Promising bridge to pills.
Read the study ↗Proapoptotic Peptide for Selective Killing of White Fat
Findings: Reduces visceral fat (worst kind), enhances metabolism, targeted weight loss.
White fat clogs organs; brown fat burns calories. FTPP kills white fat's support system. In fat-cell cultures and animals, it triggered death signals, shrinking fat pads 25-30%. Blood vessels in fat died selectively—others untouched. Obese rats slimmed, moved better. Mechanism: binds fat receptor, amps death proteins. Safety: low doses fine, higher needed watching kidneys (dehydration risk). Human trials eyed for morbid obesity. Picture erasing belly pooch without gym marathons. For 9th graders, it's science fiction turning real—zap fat factories shut. Could revolutionize weight help, especially where diets fail.
Read the study ↗More references (6)
- Selective induction of apoptosis in adipose vasculature, 2015
- Prohibitin as a receptor for Adipotide, 2014
- Targeting the adipose tissue in treatment of obesity, 2013
- Targeted Proapoptotic Peptide (Adipotide) in Non-Human Primates, 2011
- A peptide-driven drug delivery system to target white fat, 2011
- Vascular targeting of white adipose tissue, 2004
Identification
Chemistry
- common names
- Adipotide, FTPP (Fat-Targeted Proapoptotic Peptide), Prohibitin-TP01, Prohibitin-Targeting Peptide 1, TP-1, TP01
- cas
- 859216-15-2
- formula
- C₁₁₁H₂₀₆N₃₆O₂₈S₂
- molecular weight
- 2557.2-2557.22 g/mol (average: 2557.21 Da; monoisotopic: 2555.48 Da)
- sequence
- -
- source
- Synthetic chimeric peptidomimetic rationally designed and developed through combinatorial phage display library screening and chemical synthesis
- biosynthesis
- Produced via solid-phase peptide synthesis (SPPS) using orthogonal protecting group strategies to incorporate both L- and D-amino acids; not naturally occurring
Keep exploring
Related peptides
5-Amino-1MQ
5-amino-1-methylquinolinium · NNMTi
- Route
- Subcutaneous
- Dose
- 2.5 mg – 5 mg
- Cycle
- 10–20 days (based on a single 50 mg vial)
AICAR
Acadesine · AICA-Riboside
- Route
- Subcutaneous
- Dose
- 1 mg – 3 mg
- Cycle
- 8–12 weeks
AOD-9604
AOD 9604 · Tyr-hGH fragment 177-191
- Route
- Subcutaneous
- Dose
- 200 mcg – 500 mcg
- Cycle
- 8–12 weeks
Cagrilintide
NN9838 (Novo Nordisk development code) · AM833 (development designation)
- Route
- Subcutaneous
- Dose
- 300 mcg – 1.2 mg
- Cycle
- Long-term management focus